Movatterモバイル変換


[0]ホーム

URL:


TW200616679A - Modified-release preparation - Google Patents

Modified-release preparation

Info

Publication number
TW200616679A
TW200616679ATW094133910ATW94133910ATW200616679ATW 200616679 ATW200616679 ATW 200616679ATW 094133910 ATW094133910 ATW 094133910ATW 94133910 ATW94133910 ATW 94133910ATW 200616679 ATW200616679 ATW 200616679A
Authority
TW
Taiwan
Prior art keywords
substituted
compound
ring
bond
group
Prior art date
Application number
TW094133910A
Other languages
Chinese (zh)
Inventor
Akihiko Ono
Shuji Yoneyama
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals CofiledCriticalTakeda Pharmaceuticals Co
Publication of TW200616679ApublicationCriticalpatent/TW200616679A/en

Links

Classifications

Landscapes

Abstract

The present invention relates to a pharmaceutical agent comprising a combination of two or more parts comprising a compound of the formula: , wherein R1 represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X represents a bond, or the like; m represents an integer of 0 to 3; Y represents an oxygen atom or the like; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group; X1 represents a bond or the like; R2 represents a hydrogen atom or the like; W represents a bond or the like; R3 represents a group of the formula: -OR8 (R8 represents a hydrogen atom or a hydrocarbon group which may be substituted) or the like; or a salt thereof, said two or more parts have mutually different release rates of the compound or a salt thereof. According to the present invention, a pharmaceutical agent comprising a nitrogen containing 5-membered heterocyclic compound useful as an agent for the prophylaxis or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance, inflammatory diseases, arteriosclerosis and the like, which has improved sustainability of an effective blood concentration of the compound, can be provided.
TW094133910A2004-09-302005-09-29Modified-release preparationTW200616679A (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
JP20042872442004-09-30

Publications (1)

Publication NumberPublication Date
TW200616679Atrue TW200616679A (en)2006-06-01

Family

ID=36119292

Family Applications (1)

Application NumberTitlePriority DateFiling Date
TW094133910ATW200616679A (en)2004-09-302005-09-29Modified-release preparation

Country Status (2)

CountryLink
TW (1)TW200616679A (en)
WO (1)WO2006036007A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JP5366558B2 (en)*2006-12-282013-12-11武田薬品工業株式会社 Orally disintegrating solid preparation
US8551524B2 (en)*2008-03-142013-10-08Iycus, LlcAnti-diabetic combinations
EP2486918A4 (en)2009-10-092014-02-26Yungjin Pharmaceutical Co LtdPharmaceutical composition with both immediate and extended release characteristics
PH12012500886A1 (en)2009-11-032012-11-26Lupin LtdModified release formulation of lacosamide
WO2011101863A2 (en)*2010-02-192011-08-25Cadila Healthcare LimitedExtended release pharmaceutical compositions of lacosamide
CA3008170A1 (en)2015-12-302017-07-06Adamas Pharmaceuticals, Inc.Methods and compositions for the treatment of seizure-related disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
NZ519238A (en)*1999-11-102003-11-28Takeda Chemical Industries Ltd5-membered N-heterocyclic compounds with hypolglycemic and hypolipidemic activity
EP1541564A1 (en)*2002-09-102005-06-15Takeda Pharmaceutical Company LimitedFive-membered heterocyclic compounds

Also Published As

Publication numberPublication date
WO2006036007A3 (en)2006-09-14
WO2006036007A2 (en)2006-04-06

Similar Documents

PublicationPublication DateTitle
MY142807A (en)Benzimidazole derivative and use thereof.
MD20110063A2 (en)Herbicidal compositions containing benzoylpyrazole compounds
TW200510381A (en)Novel 2-pyridinecarboxamide derivatives
MX2009010024A (en)Novel adenine compound.
TW200745034A (en)New compounds
WO2005097129A3 (en)6-azaindole compound
EA200601830A1 (en) ORT-SUBSTITUTED ARYL OR HETEROARYL AMIDAL COMPOUNDS
MY153045A (en)Oxopyrazine derivative and herbicide
UA95255C2 (en)Azole and thiazole derivatives and their use
WO2008108378A3 (en)Bicyclic oxomorpholine derivative
EP1679309A4 (en)Antistress drug and medical use thereof
WO2004037181A3 (en)Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
TW200505919A (en)DPP-IV inhibitors
MY173930A (en)Crystalline solvates and complexes of (is)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
EP1961734A4 (en) AMINO COMPOUND AND USE THEREOF FOR MEDICAL APPLICATIONS
GB0129476D0 (en)Organic compounds
TNSN07397A1 (en)Acetylene derivatives
DE602008001725D1 (en) 1- (1-BENZYLPIPERIDIN-4-YL) BENZIMIDAZOLE-5-CARBOXYLENE DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS
GEP20125637B (en)Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
TW200744589A (en)Pharmaceutical composition
WO2008126901A1 (en)Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
MX2010001566A (en)Aminopyrazole amide derivative.
MY139461A (en)Condensed furan compounds
EP1775289A4 (en)Novel imidazolidine derivatives
DK2000473T3 (en) Trehalose compound and drug comprising the compound

[8]ページ先頭

©2009-2025 Movatter.jp